{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:24:40Z","timestamp":1788996280376,"version":"build-2803163510"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1910602"],"award-info":[{"award-number":["W81XWH1910602"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["HT94252310067"],"award-info":[{"award-number":["HT94252310067"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1819794"],"award-info":[{"award-number":["1819794"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["2035560"],"award-info":[{"award-number":["2035560"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA287211"],"award-info":[{"award-number":["R21CA287211"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA293765"],"award-info":[{"award-number":["R21CA293765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R43CA9622551"],"award-info":[{"award-number":["R43CA9622551"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R43CA250941"],"award-info":[{"award-number":["R43CA250941"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA188382"],"award-info":[{"award-number":["R01CA188382"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.xcrm.2026.102839","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:03:33Z","timestamp":1780499013000},"page":"102839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory"],"prefix":"10.1016","volume":"7","author":[{"given":"Shradha","family":"Khanduja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars M.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Van Dessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9302-9712","authenticated-orcid":false,"given":"Neil S.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102839_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102839_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/v13061128","article-title":"Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances","volume":"13","author":"Kwan","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2026.102839_bib3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41598-019-57240-x","article-title":"Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy","volume":"10","author":"Mahasa","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102839_bib6","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/jgm.800","article-title":"Oncolytic virotherapy for cancer treatment: challenges and solutions","volume":"7","author":"Davis","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.xcrm.2026.102839_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13122192","article-title":"Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy","volume":"13","author":"Reale","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xcrm.2026.102839_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv. Virol."},{"key":"10.1016\/j.xcrm.2026.102839_bib9","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/mt.2009.194","article-title":"Cell carriers for oncolytic viruses: Fed Ex for cancer therapy","volume":"17","author":"Willmon","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mt.6300039","article-title":"Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity","volume":"15","author":"Power","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib11","first-page":"47","article-title":"Cell carriers for oncolytic viruses: current challenges and future directions","volume":"2","author":"Roy","year":"2013","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.xcrm.2026.102839_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061383","article-title":"Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102839_bib13","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.20892\/j.issn.2095-3941.2024.0390","article-title":"Improving systemic delivery of oncolytic virus by cellular carriers","volume":"21","author":"Peng","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.xcrm.2026.102839_bib14","first-page":"5188","article-title":"Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors","volume":"63","author":"Forbes","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102839_bib15","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1038\/s41467-021-26367-9","article-title":"Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases","volume":"12","author":"Raman","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102839_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.1090124","article-title":"Bacterial invasion: The paradigms of enteroinvasive pathogens","volume":"304","author":"Cossart","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102839_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cell.2006.02.012","article-title":"Bacterial adhesion and entry into host cells","volume":"124","author":"Pizarro-Cerd\u00e1","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102839_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.chom.2017.02.005","article-title":"Salmonella enterica Remodels the Host Cell Endosomal System for Efficient Intravacuolar Nutrition","volume":"21","author":"Liss","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.xcrm.2026.102839_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004374","article-title":"Reorganization of the endosomal system in Salmonella-infected cells: the ultrastructure of Salmonella-induced tubular compartments","volume":"10","author":"Krieger","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.xcrm.2026.102839_bib20","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1111\/j.1600-0854.2008.00821.x","article-title":"Dynamic remodeling of the endosomal system during formation of Salmonella-induced filaments by intracellular Salmonella enterica","volume":"9","author":"Rajashekar","year":"2008","journal-title":"Traffic"},{"key":"10.1016\/j.xcrm.2026.102839_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102839_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib23","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26403","article-title":"Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation","volume":"2","author":"Spel","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.xcrm.2026.102839_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw261","article-title":"Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment","volume":"109","author":"Gulley","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2026.102839_bib25","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1128\/JVI.06208-11","article-title":"Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid","volume":"86","author":"Allaume","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102839_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1308890","article-title":"Oncolytic virotherapy in cancer treatment: challenges and optimization prospects","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102839_bib27","doi-asserted-by":"crossref","first-page":"47287","DOI":"10.18632\/oncotarget.10075","article-title":"A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2026.102839_bib28","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.7150\/jca.46463","article-title":"A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy","volume":"11","author":"Wang","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41551-025-01476-8","article-title":"Engineered bacteria launch and control an oncolytic virus","volume":"10","author":"Singer","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xcrm.2026.102839_bib30","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1158\/1078-0432.CCR-11-2325","article-title":"Molecular Pathways: Rodent Parvoviruses\u2014Mechanisms of Oncolysis and Prospects for Clinical Cancer Treatment","volume":"18","author":"N\u00fcesch","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102839_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12985-014-0223-y","article-title":"Oncolytic parvoviruses: from basic virology to clinical applications","volume":"12","author":"Marchini","year":"2015","journal-title":"Virol. J."},{"key":"10.1016\/j.xcrm.2026.102839_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399404008026","article-title":"Parvovirus vectors: use and optimisation in cancer gene therapy","volume":"6","author":"Blechacz","year":"2004","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102839_bib33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ijc.2910550427","article-title":"Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures","volume":"55","author":"Van Pachterbeke","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jgm.653","article-title":"In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA","volume":"7","author":"El Bakkouri","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.xcrm.2026.102839_bib35","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1002\/ijc.23472","article-title":"Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity","volume":"122","author":"Raykov","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00202","article-title":"Oncolytic Viruses\u2014Natural and Genetically Engineered Cancer Immunotherapies","volume":"7","author":"Jhawar","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102839_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cytogfr.2010.02.011","article-title":"Oncolytic parvoviruses as cancer therapeutics","volume":"21","author":"Rommelaere","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.xcrm.2026.102839_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2026.102839_bib39","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/sj.gt.3301477","article-title":"A novel MVMp-based vector system specifically designed to reduce the risk of replication-competent virus generation by homologous recombination","volume":"8","author":"Dupont","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/v11060562","article-title":"H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future","volume":"11","author":"Bretscher","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2026.102839_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009002","article-title":"The NS1 protein of the parvovirus MVM Aids in the localization of the viral genome to cellular sites of DNA damage","volume":"16","author":"Majumder","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.xcrm.2026.102839_bib42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/1566523043346228","article-title":"Cancer gene therapy through autonomous parvovirus--mediated gene transfer","volume":"4","author":"Cornelis","year":"2004","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0065-3527(07)70005-2","article-title":"Parvoviral host range and cell entry mechanisms","volume":"70","author":"Cotmore","year":"2007","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.xcrm.2026.102839_bib44","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012989","article-title":"Parvovirus diversity and DNA damage responses","volume":"5","author":"Cotmore","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.xcrm.2026.102839_bib45","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1128\/jvi.71.7.5323-5329.1997","article-title":"The NS1 protein of the autonomous parvovirus minute virus of mice blocks cellular DNA replication: a consequence of lesions to the chromatin?","volume":"71","author":"Op De Beeck","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102839_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/v9110313","article-title":"Protoparvovirus Cell Entry","volume":"9","author":"Ros","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2026.102839_bib47","series-title":"The parvoviruses.","first-page":"365","article-title":"Parvovirus oncosuppression","author":"Cornelis","year":"2006"},{"key":"10.1016\/j.xcrm.2026.102839_bib48","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1128\/JVI.03688-13","article-title":"Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer","volume":"88","author":"Angelova","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102839_bib49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40425-018-0381-3","article-title":"White paper on microbial anti-cancer therapy and prevention","volume":"6","author":"Forbes","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib50","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","article-title":"Recent advances of oncolytic virus in cancer therapy","volume":"16","author":"Mondal","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.xcrm.2026.102839_bib51","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102839_bib52","doi-asserted-by":"crossref","first-page":"8231","DOI":"10.1007\/s00253-020-10802-w","article-title":"The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them","volume":"104","author":"Hu","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102839_bib53","article-title":"Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic","volume":"7","author":"Zou","year":"2023","journal-title":"Glob. Chall."},{"key":"10.1016\/j.xcrm.2026.102839_bib54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fimmu.2020.00683","article-title":"Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102839_bib55","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102839_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: Challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib57","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17425247.2019.1617269","article-title":"Achieving systemic delivery of oncolytic viruses","volume":"16","author":"Hill","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.xcrm.2026.102839_bib58","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1128\/JVI.02601-06","article-title":"Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells","volume":"81","author":"Di Piazza","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102839_bib59","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/1471-2407-11-464","article-title":"Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1","volume":"11","author":"Moehler","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib60","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/cgt.2012.20","article-title":"Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection","volume":"19","author":"Grekova","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib61","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4161\/cbt.10.12.13455","article-title":"Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent","volume":"10","author":"Grekova","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib62","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","article-title":"Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones","volume":"26","author":"Martin","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the Immune System: The Dynamic Duo","volume":"17","author":"Lemos De Matos","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.102839_bib64","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1089\/hum.2005.16.996","article-title":"Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells","volume":"16","author":"Moehler","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib65","first-page":"4192","article-title":"Advances in the clinical development of oncolytic viruses","volume":"14","author":"Li","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.xcrm.2026.102839_bib66","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<584::AID-IJC15>3.0.CO;2-9","article-title":"Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection","volume":"75","author":"Faisst","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib67","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/jgo.2016.09.07","article-title":"Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.xcrm.2026.102839_bib68","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12254-018-0431-z","article-title":"Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?","volume":"11","author":"Pinter","year":"2018","journal-title":"Memo"},{"key":"10.1016\/j.xcrm.2026.102839_bib69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.cgt.7700288","article-title":"Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors","volume":"8","author":"Moehler","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib70","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.3748\/wjg.14.3819","article-title":"Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein","volume":"14","author":"Sieben","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.xcrm.2026.102839_bib71","first-page":"23","article-title":"[p53 gene expression of human hepatoma cell lines and their sensitivities to parvovirus H-1]","volume":"32","author":"Guo","year":"1999","journal-title":"Shi yan sheng wu xue bao"},{"key":"10.1016\/j.xcrm.2026.102839_bib72","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1128\/JVI.79.4.2274-2286.2005","article-title":"Expression Profiling of Human Hepatoma Cells Reveals Global Repression of Genes Involved in Cell Proliferation, Growth, and Apoptosis upon Infection with Parvovirus H-1","volume":"79","author":"Li","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102839_bib73","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/ijc.24992","article-title":"SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV","volume":"126","author":"Dempe","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1386699","article-title":"Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments","volume":"14","author":"Bugazia","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102839_bib75","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2008.20.7753","article-title":"Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005","volume":"27","author":"Altekruse","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102839_bib76","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2024.42.3_suppl.633","article-title":"Trends in incidence and survival of early-stage pancreatic ductal adenocarcinoma in the United States","volume":"42","author":"Perrotta","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102839_bib77","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update","volume":"42","author":"Gordan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102839_bib78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0033-1333648","article-title":"Chemoembolization of hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2013","journal-title":"Semin. Interv. Radiol."},{"key":"10.1016\/j.xcrm.2026.102839_bib79","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102839_bib80","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2022.06.042","article-title":"Impact of first-line FOLFIRINOX versus Gemcitabine\/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry","volume":"174","author":"Santucci","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102839_bib81","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","article-title":"Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I\/IIa Glioblastoma Trial","volume":"25","author":"Geletneky","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109813","article-title":"Intracellular delivery of oncolytic viruses with engineered Salmonella causes viral replication and cell death","volume":"27","author":"Khanduja","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.xcrm.2026.102839_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102670","article-title":"RecBCD- RecFOR-independent pathway of homologous recombination in Escherichia coli","volume":"83","author":"Buljuba\u0161i\u0107","year":"2019","journal-title":"DNA Repair"},{"key":"10.1016\/j.xcrm.2026.102839_bib84","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/genetics\/146.3.751","article-title":"Pathways for homologous recombination between chromosomal direct repeats in Salmonella typhimurium","volume":"146","author":"Galitski","year":"1997","journal-title":"Genetics"},{"key":"10.1016\/j.xcrm.2026.102839_bib85","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1128\/mr.58.3.401-465.1994","article-title":"Biochemistry of homologous recombination in Escherichia coli","volume":"58","author":"Kowalczykowski","year":"1994","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.xcrm.2026.102839_bib86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0378-1119(85)90170-2","article-title":"An Escherichia coli recBCsbcBrecF host permits the deletion-resistant propagation of plasmid clones containing the 5'-terminal palindrome of minute virus of mice","volume":"35","author":"Boissy","year":"1985","journal-title":"Gene"},{"key":"10.1016\/j.xcrm.2026.102839_bib87","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1128\/jvi.44.3.993-1002.1982","article-title":"Lytic action of cloned phi X174 gene E","volume":"44","author":"Young","year":"1982","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.102839_bib88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ymthe.2024.12.038","article-title":"Controlling intracellular protein delivery, tumor colonization and tissue distribution using flhDC in clinically relevant \u0394sseJ Salmonella","volume":"33","author":"Raman","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102839_bib89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-009-0451-9","article-title":"Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures","volume":"121","author":"Muharram","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2026.102839_bib90","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.xcrm.2026.102839_bib91","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40164-021-00252-z","article-title":"Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies","volume":"10","author":"Zhu","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102839_bib92","doi-asserted-by":"crossref","DOI":"10.1111\/1751-7915.14461","article-title":"Controlled production of lipopolysaccharides increases immune activation in Salmonella treatments of cancer","volume":"17","author":"Howell","year":"2024","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102839_bib93","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.89828","article-title":"Dynamics of macrophage polarization support Salmonella persistence in a whole living organism","volume":"13","author":"Leiba","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2026.102839_bib94","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/JB.184.2.592-595.2002","article-title":"Role of the RecBCD recombination pathway in Salmonella virulence","volume":"184","author":"Cano","year":"2002","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.xcrm.2026.102839_bib95","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1365-2958.1993.tb01184.x","article-title":"Recombination-deficient mutants of Salmonella typhimurium are avirulent and sensitive to the oxidative burst of macrophages","volume":"7","author":"Buchmeier","year":"1993","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.xcrm.2026.102839_bib96","article-title":"Moving oncolytic viruses into the clinic: clinical-grade production purification and characterization of diverse oncolytic viruses","volume":"3","author":"Ungerechts","year":"2016","journal-title":"Mol Ther-Meth Clin D"},{"key":"10.1016\/j.xcrm.2026.102839_bib97","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41596-024-00985-1","article-title":"Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy","volume":"19","author":"Gujar","year":"2024","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102839_bib98","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.102839_bib99","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0378-1119(90)90464-3","article-title":"Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains","volume":"94","author":"Gal\u00e1n","year":"1990","journal-title":"Gene"},{"key":"10.1016\/j.xcrm.2026.102839_bib100","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1534\/genetics.110.120782","article-title":"Lambda red recombineering in Escherichia coli occurs through a fully single-stranded intermediate","volume":"186","author":"Mosberg","year":"2010","journal-title":"Genetics"},{"key":"10.1016\/j.xcrm.2026.102839_bib101","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.err107714","article-title":"Erratum: Detergent Lysis of Tissue Culture Cells for Immunoprecipitation","volume":"2021","author":"DeCaprio","year":"2021","journal-title":"Cold Spring Harb. Protoc."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:46:44Z","timestamp":1785883604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126002569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666379126002569"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102839","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102839"}}